Currently, available targeted therapies for metastatic RCC, such as immune checkpoint inhibitors, mTOR inhibitors, or VEGF tyrosine kinase inhibitors, are routinely administered in clinical practice, yet no predictive biomarkers are used to guide the selection of those targeted treatments [5]. This evidence concerns the gene VEGFA and renal cell carcinoma.